Biogenera

BIOGENERA SpA is an innovative SME operating in the pharmaceutical biotechnology sector that has created and developed MyGenera, a unique and proprietary platform for a new era of patented personalized DNA drugs for the treatment of incurable diseases.

The company is in the final stages of its path to listing on Euronext Paris (Europe's most relevant market for biotech companies).

It counts on a multidisciplinary team of researchers and professionals and collaborates closely with universities and other players in the pharmaceutical industry. Its founders, Roberto Tonelli and Andrea Pession, have long careers as researchers and professors with a proven track record in pharmacology and oncology.

BIOGENERA currently has a portfolio of outright approved patents covering 45 countries internationally; in addition, Orphan Drug designations have been obtained from the European (EMA) and US (FDA) drug regulatory agencies.

Capital raising in the form of equity crowdfunding will support the costs for the multi-center Phase 1 clinical trial of the anti-cancer drug BGA002 for aggressive pediatric cancers in various European countries and the US.

It adopts a B2B business model and intends to finalize licensing agreements with pharmaceutical companies globally for the drug BGA002 (in clinical phase 1) and other new drugs for final clinical development and commercialization.

Tax benefits of 30 percent apply on Biogenera.

This is a marketing communication. Equity crowdfunding investments are high risk and could result in full or partial loss of invested capital. Please read the sheet containing key investment information before joining.